BACKGROUND: Carcinoembryonic antigen (CEA) flare may have a favourable response to chemotherapy, but its impact on survival is unknown. This study aimed to evaluate the incidence of CEA flare and its impact on objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). PATIENTS AND METHODS: Patients with histologically proven advanced colorectal cancer undergoing first-line chemotherapy with three or more serial CEA measurements (one at baseline and two or more during treatment) were included. Patients were grouped according to CEA kinetic as flare (F), decreasing CEA, normal baseline CEA, stable CEA and increasing CEA (I). RESULTS: From January 2000 to February 2008, 837 patients were screened of whom 670 were eligible. CEA flare occurred in 78 (11.6%) patients. On multivariate analysis, compared with patients with increasing CEA, patients with CEA flare had a significantly better ORR [I versus F: 11% versus 73%; risk ratio (RR): 27.96; 95% confidence interval (CI): 9.55-81.88; P < 0.001], PFS (median 3.1 versus 8.3 months; RR: 0.38; 95% CI: 0.26-0.56; P < 0.001) and OS (median 10.9 versus 17.7 months; RR: 0.53; 95% CI: 0.34-0.82; P < 0.001). CONCLUSIONS: Compared with patients with rising CEA, flare was an independent favourable predictive and prognostic factor for tumour response and survival.
BACKGROUND:Carcinoembryonic antigen (CEA) flare may have a favourable response to chemotherapy, but its impact on survival is unknown. This study aimed to evaluate the incidence of CEA flare and its impact on objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). PATIENTS AND METHODS: Patients with histologically proven advanced colorectal cancer undergoing first-line chemotherapy with three or more serial CEA measurements (one at baseline and two or more during treatment) were included. Patients were grouped according to CEA kinetic as flare (F), decreasing CEA, normal baseline CEA, stable CEA and increasing CEA (I). RESULTS: From January 2000 to February 2008, 837 patients were screened of whom 670 were eligible. CEA flare occurred in 78 (11.6%) patients. On multivariate analysis, compared with patients with increasing CEA, patients with CEA flare had a significantly better ORR [I versus F: 11% versus 73%; risk ratio (RR): 27.96; 95% confidence interval (CI): 9.55-81.88; P < 0.001], PFS (median 3.1 versus 8.3 months; RR: 0.38; 95% CI: 0.26-0.56; P < 0.001) and OS (median 10.9 versus 17.7 months; RR: 0.53; 95% CI: 0.34-0.82; P < 0.001). CONCLUSIONS: Compared with patients with rising CEA, flare was an independent favourable predictive and prognostic factor for tumour response and survival.
Authors: Gerald W Prager; Kira H Braemswig; Alexandra Martel; Matthias Unseld; Georg Heinze; Thomas Brodowicz; Werner Scheithauer; Gabriela Kornek; Christoph C Zielinski Journal: Cancer Sci Date: 2014-07-31 Impact factor: 6.716
Authors: Eliza A Hawkes; George Ladas; David Cunningham; Andrew G Nicholson; Katharina Wassilew; Yolanda Barbachano; Gihan Ratnayake; Sheela Rao; Ian Chau Journal: BMC Cancer Date: 2012-08-01 Impact factor: 4.430
Authors: Tobias M Gorges; Alexander Stein; Julia Quidde; Siegfried Hauch; Katharina Röck; Sabine Riethdorf; Simon A Joosse; Klaus Pantel Journal: PLoS One Date: 2016-05-16 Impact factor: 3.240
Authors: Orlando Jorge Martins Torres; Márcio Carmona Marques; Fabio Nasser Santos; Igor Correia de Farias; Anelisa Kruschewsky Coutinho; Cássio Virgílio Cavalcante de Oliveira; Antonio Nocchi Kalil; Celso Abdon Lopes de Mello; Jaime Arthur Pirola Kruger; Gustavo Dos Santos Fernandes; Claudemiro Quireze; André M Murad; Milton José de Barros E Silva; Charles Edouard Zurstrassen; Helano Carioca Freitas; Marcelo Rocha Cruz; Rui Weschenfelder; Marcelo Moura Linhares; Leonaldson Dos Santos Castro; Charles Vollmer; Elijah Dixon; Héber Salvador de Castro Ribeiro; Felipe José Fernandez Coimbra Journal: Arq Bras Cir Dig Date: 2016 Jul-Sep